A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer

Phase 2 Completed 138 enrolled Eli Lilly and Company

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether IMC-A12 or IMC-1121B (ramucirumab) with Mitoxantrone and Prednisone is effective in the treatment of metastatic androgen- independent prostate cancer (APIC).

Timeline

Start: 2008-08
Primary completion: 2011-09
Completion: 2011-09

Publications

Hussain M, Rathkopf D, Liu G, Armstrong A, Kelly WK, Ferrari A, Hainsworth J, Joshi A, Hozak RR, Yang L, Schwartz JD, Higano CS. A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer. Eur J Cancer. 2015 Sep;51(13):1714-24. doi: 10.1016/j.ejca.2015.05.019. Epub 2015 Jun 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cixutumumab	Monoclonal antibody	6 mg/kg	Intravenous
Subject	Ramucirumab	Monoclonal antibody	6 mg/kg	Intravenous
Background	Mitoxantrone	Small molecule	12 mg/m2	Intravenous
Background	Prednisone	Other / unclassified	5 mg	Oral

A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer

Summary

Timeline

Publications

Drugs

Indications